Recently, interest has been renewed towards FTis for the treatment of HRAS mutant solid tumors with encouraging results in phase II trials [25, 26], leading to FDA approval for HRAS mutant head and neck cancer, and for the Hutchinson-Gilford progeria syndrome, where the target is progerin [27]. Here, HRAS is linked to head and neck cancer.